Market Overview

Watson Confirms FDA Denies Appeal Related to Prochieve NDA for the Prevention of Preterm Birth

Related WPI
Watson Pharma Buys Uteron Pharma SA
UPDATE: Goldman Sachs Downgrades Watson Pharmaceuticals to Neutral on Limited Upside

Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that the U.S. Food and Drug Administration (FDA) denied the Company's Formal Dispute Resolution Request (FDRR) related to its pending New Drug Application (NDA) for Prochieve for the prevention of preterm birth in women with a short cervical length. The Company said it intends to review possible options related to the continued pursuit of the NDA.   Watson filed its FDRR in August of 2012.

Posted-In: News FDA


Related Articles (WPI)

View Comments and Join the Discussion!

Accuray Presents Clinical Research on its TomoTherapy Treatment

Inland Real Estate Corporation Announces Lease with Jimmy's Island Grille at St. James Crossing in Westmont